1. Home
  2. ARTL vs DRCT Comparison

ARTL vs DRCT Comparison

Compare ARTL & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARTL
  • DRCT
  • Stock Information
  • Founded
  • ARTL 2011
  • DRCT 2018
  • Country
  • ARTL United States
  • DRCT United States
  • Employees
  • ARTL 6
  • DRCT N/A
  • Industry
  • ARTL Biotechnology: Pharmaceutical Preparations
  • DRCT Computer Software: Programming Data Processing
  • Sector
  • ARTL Health Care
  • DRCT Technology
  • Exchange
  • ARTL Nasdaq
  • DRCT Nasdaq
  • Market Cap
  • ARTL 8.4M
  • DRCT 8.8M
  • IPO Year
  • ARTL N/A
  • DRCT 2022
  • Fundamental
  • Price
  • ARTL $3.97
  • DRCT $0.34
  • Analyst Decision
  • ARTL Buy
  • DRCT Strong Buy
  • Analyst Count
  • ARTL 2
  • DRCT 1
  • Target Price
  • ARTL $30.00
  • DRCT $6.00
  • AVG Volume (30 Days)
  • ARTL 69.0K
  • DRCT 6.5M
  • Earning Date
  • ARTL 11-11-2025
  • DRCT 11-11-2025
  • Dividend Yield
  • ARTL N/A
  • DRCT N/A
  • EPS Growth
  • ARTL N/A
  • DRCT N/A
  • EPS
  • ARTL N/A
  • DRCT N/A
  • Revenue
  • ARTL N/A
  • DRCT $36,459,000.00
  • Revenue This Year
  • ARTL N/A
  • DRCT $16.81
  • Revenue Next Year
  • ARTL N/A
  • DRCT $35.28
  • P/E Ratio
  • ARTL N/A
  • DRCT N/A
  • Revenue Growth
  • ARTL N/A
  • DRCT N/A
  • 52 Week Low
  • ARTL $3.91
  • DRCT $0.28
  • 52 Week High
  • ARTL $28.60
  • DRCT $6.59
  • Technical
  • Relative Strength Index (RSI)
  • ARTL 32.84
  • DRCT 45.79
  • Support Level
  • ARTL $3.94
  • DRCT $0.31
  • Resistance Level
  • ARTL $4.54
  • DRCT $0.39
  • Average True Range (ATR)
  • ARTL 0.35
  • DRCT 0.05
  • MACD
  • ARTL 0.06
  • DRCT 0.01
  • Stochastic Oscillator
  • ARTL 2.91
  • DRCT 24.22

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About DRCT Direct Digital Holdings Inc.

Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.

Share on Social Networks: